Halozyme Therapeutics Stock Analysis

Halozyme Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Halozyme Therapeutics had 171:40 split on the 10th of December 2003. Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California. Halozyme Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 145 people. To learn more about Halozyme Therapeutics call Todd Butler at 858 794 8889 or check out https://halozyme.com.

Halozyme Therapeutics Investment Alerts

Halozyme Therapeutics Upcoming and Recent Events

Halozyme Largest EPS Surprises

View All Earnings Estimates

Halozyme Therapeutics Environmental, Social, and Governance (ESG) Scores

Halozyme Therapeutics Thematic Classifications

Halozyme Stock Institutional Investors

Note, although Halozyme Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Halozyme Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.91 B.

Halozyme Profitablity

The company has Profit Margin (PM) of 0.44 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.59 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.59.

Management Efficiency

Halozyme Therapeutics has return on total asset (ROA) of 0.1816 % which means that it generated a profit of $0.1816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.9842 %, meaning that it created $1.9842 on every $100 dollars invested by stockholders. Halozyme Therapeutics' management efficiency ratios could be used to measure how well Halozyme Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of March 2025, Return On Tangible Assets is likely to grow to 0.37. Also, Return On Capital Employed is likely to grow to 0.30. At this time, Halozyme Therapeutics' Return On Tangible Assets are very stable compared to the past year. As of the 25th of March 2025, Debt To Assets is likely to grow to 0.90, while Other Current Assets are likely to drop about 22.6 M.

Technical Drivers

As of the 25th of March, Halozyme Therapeutics retains the Market Risk Adjusted Performance of 1.05, downside deviation of 1.2, and Risk Adjusted Performance of 0.2781. Halozyme Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Halozyme Therapeutics Price Movement Analysis

Halozyme Therapeutics Insider Trading Activities

Halozyme Therapeutics Outstanding Bonds

Halozyme Therapeutics Predictive Daily Indicators

Halozyme Therapeutics Corporate Filings

Halozyme Therapeutics Forecast Models

Halozyme Therapeutics' time-series forecasting models are one of many Halozyme Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Halozyme Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Halozyme Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Halozyme shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Halozyme Therapeutics. By using and applying Halozyme Stock analysis, traders can create a robust methodology for identifying Halozyme entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Halozyme analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Halozyme analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Halozyme Therapeutics stock analysis indicators help investors evaluate how Halozyme Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Halozyme Therapeutics shares will generate the highest return on investment. By understating and applying Halozyme Therapeutics stock analysis, traders can identify Halozyme Therapeutics position entry and exit signals to maximize returns.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.